Gustin Gene Polymorphism and 6-n-propylthiouracil (PROP) Taste: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Gustin Gene Polymorphism and 6-n-propylthiouracil (PROP) Taste (NCT01097915), a registered phase not stated study. The primary outcome is Association Between Gustin Gene Polymorphism and PROP Sensitivity.

2. Clinical Question

The study also considers whether PROP sensitivity is associated with salivary zinc ion concentration and BMI. Other listed outcome areas concern tongue recordings, fungiform papilla density, and perception of sweet, sour, salty, bitter and umami tastes, including changes associated with L-arginine supplementation. These additional questions broaden the scope beyond the primary genetic association, but the registry record does not report their numerical findings.

The groups distinguish levels of perceived PROP sensitivity; they do not establish that sensitivity causes differences in genetic, physiological or other measured characteristics. Since allocation is not stated and the record does not describe a like-for-like control comparison, the comparisons should be read as associations among measured characteristics rather than effects of assigned treatments.

3. Trial Design

The registry describes a completed study with enrollment of 170 participants, sponsored by the University of Cagliari. The recorded start is 2009-10 and the primary completion is 2009-12. The primary outcome timeframe is listed as 7 months. The registry does not explain how that timeframe relates to the recorded study dates, so those entries should be treated as distinct reported details rather than used to infer an individual participant’s follow-up schedule.

The study evaluates possible associations between PROP taste sensitivity and the gustin gene polymorphism rs2274333 (A/G), salivary zinc ion concentration and BMI. The record describes estimating taste intensity evoked by PROP and NaCl solutions to classify PROP status, then performing molecular analysis of the gustin gene polymorphism using PCR. Tongue monophasic potentials are also described as a way to evaluate individual variation in PROP sensitivity.

Participants are categorized as Super Tasters, Medium Tasters or Non Tasters. The registry description defines the first two groups by whether PROP is perceived as extremely or moderately bitter; non-tasters are described as non-sensitive. Allocation is not stated, and the record explicitly does not describe a randomized, like-for-like control comparison. The categories therefore represent observed sensitivity groups, not treatment assignments.

Additional outcome areas include saliva zinc concentration, BMI, electrophysiological recordings, fungiform papilla density and taste perception across several taste qualities, including changes due to L-arginine supplementation. The record lists six outcome measures and six analyses, but the detailed analysis methods, analysis populations and numerical outcome findings are not reported in the registry record. No protocol-based sample-size justification is reported. Planning calculations based on an observed effect are illustrations, not evidence of the study’s original design target or observed power.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: Caucasian and were originally from Sardinia, Italy. Participants between 20-30 years were eligible for the study.

6. Primary Endpoint

The registry lists the primary outcome as Association Between Gustin Gene Polymorphism and PROP Sensitivity, measured over 7 months.

The primary endpoint concerns the association between gustin gene polymorphism and PROP sensitivity. Its stated unit is percentage of participants. PROP sensitivity is assessed by estimating the perceived intensity of PROP and NaCl solutions, with participants classified according to their reported PROP taste sensitivity. The genetic component concerns rs2274333 (A/G) in the gustin, or CA6, gene, which the registry describes as coding for a salivary protein.

A percentage can describe the proportion of participants in a specified category, but interpreting an association requires knowing how those proportions are distributed across the relevant sensitivity and genotype groups. The registry record does not report those category counts, percentages, uncertainty intervals or a statistical test for the primary association. As a result, the size and precision of the association cannot be assessed from the record’s posted primary outcome information.

The endpoint is relevant to the stated study question because it links a measured taste phenotype with a genetic characteristic. The registry gives biological context by describing gustin as a protein suggested to promote taste-bud growth and development. That context explains why the association was investigated; it does not establish that the polymorphism changes taste sensitivity. The endpoint is an association measure, not a treatment-effect measure, and the record does not provide results that would resolve the primary question.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry frames the primary question as an association and expresses the endpoint as a percentage of participants. Understanding such an endpoint involves distinguishing the observed proportion from the uncertainty around it and from a comparison between groups. The primary numerical results needed to make those distinctions are not reported in the registry record.

What does a percentage describe?

A percentage describes how many people in a defined group meet a specified classification, relative to the number of people assessed in that group. Its meaning depends on a clear definition of both the classification and the denominator. In this study, the registry describes PROP sensitivity categories and a genetic characteristic, but does not report the corresponding group counts or percentages for the primary outcome. Without those details, a reader cannot reconstruct the distribution or judge whether categories were represented evenly.

Percentages are descriptive summaries. To answer an association question, the relevant proportions need to be compared across the genetic or taste-sensitivity groups, with a statistical method appropriate to the data structure. The registry record does not report the test, model or effect measure used for that comparison. It is therefore not possible to tell whether the posted endpoint is intended as a simple descriptive proportion, a contrast between proportions or a result from a model.

What would uncertainty add?

A confidence interval expresses the statistical uncertainty around an estimate under a specified analysis and its assumptions. A narrow interval generally indicates greater precision than a wide interval; an interval that includes values compatible with little or no association may leave substantial uncertainty about the direction or size of the relationship. These are general principles. The registry record does not report a confidence interval for the primary endpoint, so its precision cannot be assessed.

A p-value, when used, assesses how compatible the observed data are with a specified null hypothesis under the analysis assumptions. It does not measure the size or importance of an association, and it does not establish causality. No primary p-value is reported in the registry record. The absence of a reported p-value should not be treated as a result or translated into a claim about statistical significance.

Why does the comparison structure matter?

The registry characterizes the study as not being a randomized comparison, and allocation is not stated. The three taste categories are classifications of participants by perceived sensitivity. They are not like-for-like control groups created through random assignment. In general, differences among observational groups can reflect the characteristic being studied, other participant characteristics, or both. Adjustment can address measured factors under suitable assumptions, but the registry record does not report whether adjusted analyses were conducted or which factors, if any, were included.

The biological explanation in the record describes gustin as a salivary protein suggested to promote taste-bud growth and development. This is a rationale for investigating a genetic association, not a statistical method and not evidence of a causal pathway in these participants. The endpoint should therefore be read as a question about co-occurrence of measured characteristics, unless stronger design and analysis details are reported elsewhere in the record.

How should planning calculations be read?

Sample-size calculations can illustrate how many participants per arm might be needed under specified assumptions about significance level, allocation and the effect to be detected. The registry’s calculation assumptions describe a two-sided significance level of 0.05, equal allocation between two arms and a normal approximation, with the target effect expressed as a fraction of the observed effect. Such calculations are planning illustrations, not the study’s original sample-size justification and not observed power. They cannot show that an analysis was adequately powered after the fact. The numerical planning outputs and a protocol-based sample-size justification are not reported in the registry record.

These assumptions also need to be interpreted in light of the study design. The registry describes sensitivity categories rather than a randomized two-arm treatment comparison. A calculation framed around equal allocation between two arms does not, by itself, describe the allocation or analysis actually used in this study. Any sample-size illustration should be treated as a conditional planning exercise, not as a reconstruction of the study protocol.

What does the outcome scope imply?

The registry lists outcome areas covering the genetic association, saliva zinc, BMI, electrophysiological recordings, fungiform papilla density and taste perception, including changes due to L-arginine supplementation. Several outcomes can involve different measurements and different statistical questions. A percentage endpoint is not automatically an appropriate summary for continuous measurements such as a concentration or BMI; each outcome requires a method matching its scale and distribution. The record does not report the detailed methods used for these additional analyses.

Multiple outcome questions also raise the general issue of multiplicity: testing many relationships can increase the chance of at least one apparently unusual result if all tests are interpreted without accounting for the number of tests. Whether and how that issue was addressed is not reported in the registry record. The count of outcomes alone does not reveal the dependence among tests, the analysis hierarchy or any adjustment approach.

Finally, interpretation depends on who contributed data to each analysis and how incomplete measurements were handled. The registry record does not report analysis populations, exclusions, missing-data procedures or the number assessed for each outcome. Those details matter because the denominator can differ across measures and because missingness can affect the representativeness of a percentage or comparison. Without them, the primary result’s precision and the comparability of outcome-specific analyses remain unclear.

10. Multiplicity, Missing Data and Analysis Populations

The registry lists six outcome measures and six analyses. It names additional outcome areas concerning salivary zinc, BMI, tongue electrophysiology, fungiform papilla density, and taste perception, including changes due to L-arginine supplementation. The record does not explain how the primary question was prioritized relative to these other questions, whether analyses were prespecified in a hierarchy, or whether any adjustment for multiple testing was used. Those details are not reported in the registry record.

Multiplicity matters in general when several hypotheses are tested: looking across many results can make an isolated finding appear more compelling than it would in a single prespecified test. The appropriate interpretation depends on the number and dependence of tests, the analysis plan and the purpose of the analyses. The outcome count alone cannot establish whether multiplicity was controlled or whether it materially affects interpretation.

The registry does not report the primary numerical result, group denominators, confidence interval or p-value. It also does not report the analysis populations for each outcome, participant exclusions, or how missing measurements were handled. These omissions limit assessment of which participants contributed to each analysis and whether outcome-specific denominators differed.

The record does not report whether analyses were adjusted for other participant characteristics, how the statistical model was selected, or how deviations from any planned analysis were handled. A protocol-based sample-size justification is also not reported. These details should not be inferred from enrollment or from planning illustrations. Without a stated missing-data approach and analysis population, the robustness of the reported outcome summaries cannot be evaluated from the registry record.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

The registry lists adverse-event figures for Super Tasters, Medium Tasters and Non Tasters. For serious adverse events, the numbers at risk are 27, 28 and 20, respectively, and the number affected is 0 in each group. For other adverse events, the numbers at risk are also 27, 28 and 20, with 0 affected in each group. These are the counts recorded for the listed groups.

Zero recorded events does not establish that an event could not occur, and it does not show that the study was designed to compare safety between the taste categories. The groups are sensitivity classifications, not randomized treatment arms. The record does not describe a treatment safety comparison or provide further detail about how adverse events were collected.

Death counts are not reported in the registry record. The available event counts should therefore be read narrowly: they describe the entries recorded for the listed groups, rather than proving an absence of all possible harms or addressing safety beyond the recorded information.

12. What the Result Does, and Does Not, Mean

The registry record documents a completed investigation of PROP taste sensitivity and its possible association with the gustin gene polymorphism rs2274333 (A/G). It describes how taste sensitivity was classified and states that genetic analysis was performed using PCR. It also identifies related measures and outcome areas. These details establish what the investigators set out to examine, but they do not establish the study’s findings.

The numerical primary outcome results are not reported in the registry record. No primary percentages, effect estimate, confidence interval or p-value are given. Readers therefore cannot determine the direction or size of the association from the posted primary outcome information, or assess its statistical precision. The missing result should not be interpreted as evidence for no association or as evidence for an association.

Even if a numerical association were available, an association between genetic status and perceived taste sensitivity would not by itself prove that the genetic characteristic caused the difference. The record does not describe randomized assignment, and the taste groups are based on observed sensitivity. General causal interpretation requires attention to study design and other factors that could influence the measured characteristics.

The registry’s biological rationale describes gustin as a salivary protein suggested to promote taste-bud growth and development. A plausible rationale can motivate a research question, but it is distinct from a result. The record also lists other questions about zinc, BMI, electrophysiological recordings, papilla density and taste perception. Numerical findings for those outcome areas are not reported in the registry record, so they cannot be used to extend the interpretation.

Enrollment of 170 and the completed status describe the study’s scale and status, not the strength of evidence for any particular relationship. Planning calculations based on an observed effect are illustrations under specified assumptions; they are not observed power and do not replace reported estimates and uncertainty. The defensible reading is therefore limited: the registry describes a study designed to assess several relationships, but does not report the numerical results needed to characterize those relationships.

13. Why This Trial Matters Statistically

This study is statistically interesting because it connects several types of measurement: a taste-sensitivity classification, a genetic polymorphism, salivary zinc concentration, BMI and physiological recordings from the tongue. Questions linking biological characteristics with a measured sensory phenotype require clear definitions of the groups, transparent denominators and estimates that convey uncertainty. The registry supplies a description of the question and measurement approach, but not the numerical primary result needed to evaluate the association.

The study also illustrates why a group comparison is not automatically a randomized experiment. Super Tasters, Medium Tasters and Non Tasters are categories based on perceived PROP sensitivity. Since allocation is not stated and the record does not describe a like-for-like control comparison, differences among categories should be understood as observational comparisons. In general, this makes careful attention to potential confounding and the analytic method important.

A broad set of outcomes creates further statistical questions. Different measures may require different summaries and models, while multiple analyses raise questions about prespecification and multiplicity. The registry lists six outcome measures and six analyses but does not report the detailed statistical plan, adjustment methods or analysis populations. Those omissions limit independent appraisal of how the study’s multiple questions were handled.

For biostatisticians and clinical researchers, the record is a reminder that a clear biological rationale and a completed study do not alone communicate evidential strength. Interpretation depends on the reported estimate, its precision, the denominator, missing-data handling and the relationship between the analysis and the design. In this case, the record establishes the questions and classifications but does not report the results required to judge the magnitude or precision of the primary association.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The principal limitation of the registry record for statistical interpretation is that it does not report numerical primary outcome results. Group-specific percentages, counts for the primary association, an effect estimate and measures of uncertainty are absent. Numerical results for the listed secondary outcome areas are also not reported in the registry record. This prevents evaluation of direction, magnitude and precision.

The record gives limited information about the participant population beyond enrollment of 170 and the listed condition of dysgeusia. Eligibility criteria, demographic characteristics and the number contributing data to each outcome are not reported in the registry record. Without outcome-specific denominators, it is not possible to assess whether the analyzed participants were the same across measures.

Allocation is not stated, and the registry explicitly does not describe a randomized, like-for-like control comparison. The taste categories are observed classifications. The statistical plan, covariate adjustment, multiplicity handling, missing-data methods and analysis populations are not reported in the registry record. These gaps limit assessment of confounding, selection and robustness.

The record lists a 7 months timeframe for the primary outcome, alongside study dates of 2009-10 and 2009-12, but does not explain the relationship between those entries. It also does not report a protocol-based sample-size justification. Planning calculations are illustrations based on an observed effect and stated assumptions, not a record of the original design or observed power. These limitations concern the information available in the registry record and should not be taken as proof that the unreported methods were not used.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Gustin Gene Polymorphism and 6-n-propylthiouracil (PROP) Taste — NCT01097915.
• Registry record last updated 2018-12-21; status last verified 2018-12.
• Results first posted 2016-12-21.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

NCT01097915 is a completed study sponsored by the University of Cagliari, with enrollment of 170 participants. The registry records a start date of 2009-10 and primary completion in 2009-12. Dysgeusia is the listed condition.

The primary question concerns association between PROP sensitivity and the gustin gene polymorphism rs2274333 (A/G), with the endpoint expressed as a percentage of participants. Taste sensitivity is classified as Super Tasters, Medium Tasters or Non Tasters. The registry describes estimating perception of PROP and NaCl solutions and performing genetic analysis using PCR.

Other listed outcome areas include salivary zinc, BMI, tongue electrophysiology, fungiform papilla density and taste perception, including changes due to L-arginine supplementation. The record lists six outcome measures and six analyses. Numerical primary and secondary results, detailed statistical methods, missing-data handling and analysis populations are not reported in the registry record.